玻璃体内注射地塞米松植入物治疗难治性白塞氏后葡萄膜炎：一年随访结果
Intravitreal Dexamethasone Implant for Treatment of Refractory Behçet Posterior Uveitis: One-year Follow-up Results.
作者信息
Coşkun Erol, Celemler Pelin, Kimyon Gezmis, Öner Veysi, Kisacik Bunyamin, Erbagci Ibrahim, Onat Ahmet Mesut
机构信息
a Department of Ophthalmology , Gaziantep University Medicine School , Gaziantep , Turkey .
c Gaziantep University Medicine School, Department of Rheumatology , Gaziantep , Turkey.
出版信息
Ocul Immunol Inflamm. 2015;23(6):437-43. doi: 10.3109/09273948.2015.1042167. Epub 2015 Oct 15.
PURPOSE
To investigate the results of dexamethasone (DEX) implant in the treatment of eyes with refractory Behçet posterior uveitis.
METHODS
A total of 17 eyes of 12 patients with active Behçet posterior uveitis were enrolled in the study. A single intravitreal injection of DEX implant was applied to each eye. Best corrected visual acuity (BCVA), central macular thickness (CMT), vitreous haze score, and intraocular pressure (IOP) were determined, at baseline and control visits of months 1, 3, 6, and 12.
RESULTS
The mean BCVA was significantly increased from baseline at each control visit (all p < 0.05). The mean CMT and vitreous haze score were significantly decreased from baseline at each control visit (all p < 0.05). Three eyes showed IOP spikes requiring topical anti-glaucomatous treatment.
CONCLUSIONS
A single injection of DEX implant was safe and effective, as an additional treatment to systemic immunomodulatory drugs, in the treatment of refractory Behçet posterior uveitis, for a 6-month period.
目的
探讨地塞米松（DEX）植入物治疗难治性白塞氏病后葡萄膜炎的效果。
方法
本研究共纳入12例活动性白塞氏病后葡萄膜炎患者的17只眼。每只眼均行单次玻璃体内注射DEX植入物。在基线期以及第1、3、6和12个月的对照访视时，测定最佳矫正视力（BCVA）、中心黄斑厚度（CMT）、玻璃体混浊评分和眼压（IOP）。
结果
每次对照访视时，平均BCVA较基线期均显著提高（所有p<0.05）。每次对照访视时，平均CMT和玻璃体混浊评分较基线期均显著降低（所有p<0.05）。3只眼出现眼压峰值，需要局部抗青光眼治疗。
结论
单次注射DEX植入物作为全身免疫调节药物的辅助治疗，在治疗难治性白塞氏病后葡萄膜炎6个月期间是安全有效的。
Zotero 插件